HR and breast cancer: The value of the Oncotype DX® test was confirmed in two randomized controlled trials in women with HR+, HER2−, early BC: TAILORx, enrolling patients with node-negative (N0) disease, and RxPONDER, enrolling patients with 1–3 invaded lymph nodes (N1) (10, 17, 18).